Randolph D Glickman1, Michael Onorato2, Maria M Campos3, Michael P O'Boyle4, Ratnesh K Singh2, Thomas I Zarembinski2, Francois Binette2, Igor O Nasonkin2. 1. Department of Ophthalmology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA. 2. Lineage Cell Therapeutics, Inc., Alameda, California, USA. 3. Histopathology Core, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA. 4. Research Imaging Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Abstract
Purpose: To determine the long-term biocompatibility of HyStem® hydrogel in the rabbit eye for use as a carrier for cell or drug delivery into the ocular space. Methods: HyStem hydrogel formulation solidifies ∼20 min after reconstitution, thus can potentially form a solid deposit after injection in situ. To study the ocular disposition of fluorescein-labeled HyStem, we delivered 50 μL/eye over 1 min into the vitreous space of the rabbit. We used 3 Dutch-Belted and 3 New Zealand-pigmented rabbits, all females, delivered the gel into the right eyes, and injected 50 μL BSS Plus into the left eyes as a control. Retinal morphology was assessed by optical coherence tomography (OCT) and white light fundus photography. Fluorescence fundus photography enabled measurement of the clearance of the labeled hydrogel from the posterior chamber. Visual function was evaluated using flash and flicker electroretinography (ERG) pre- and postinjection and at weekly intervals thereafter for 6 weeks. Retinal immunohistochemistry for microglial inflammatory markers was carried out with antiglial fibrillary acidic protein (GFAP) antibody, isolectin B4 (IB4), and 4',6-diamidino-2-phenylindole (DAPI). Results: The gel was successfully delivered into the vitreous space without the formation of a discrete retinal deposit. Fundus imaging, OCT measurements of retinal thickness, and immunohistochemical data indicated an absence of retinal inflammation, and ERG indicated no impact on retinal function. The half-time of HyStem clearance calculated from the loss of fundus fluorescence was 3.9 days. Conclusions: HyStem hydrogel appears to be biocompatible in the ocular space of a large eye and safe for long-term intraocular application.
Purpose: To determine the long-term biocompatibility of HyStem® hydrogel in the rabbit eye for use as a carrier for cell or drug delivery into the ocular space. Methods: HyStem hydrogel formulation solidifies ∼20 min after reconstitution, thus can potentially form a solid deposit after injection in situ. To study the ocular disposition of fluorescein-labeled HyStem, we delivered 50 μL/eye over 1 min into the vitreous space of the rabbit. We used 3 Dutch-Belted and 3 New Zealand-pigmented rabbits, all females, delivered the gel into the right eyes, and injected 50 μL BSS Plus into the left eyes as a control. Retinal morphology was assessed by optical coherence tomography (OCT) and white light fundus photography. Fluorescence fundus photography enabled measurement of the clearance of the labeled hydrogel from the posterior chamber. Visual function was evaluated using flash and flicker electroretinography (ERG) pre- and postinjection and at weekly intervals thereafter for 6 weeks. Retinal immunohistochemistry for microglial inflammatory markers was carried out with antiglial fibrillary acidic protein (GFAP) antibody, isolectin B4 (IB4), and 4',6-diamidino-2-phenylindole (DAPI). Results: The gel was successfully delivered into the vitreous space without the formation of a discrete retinal deposit. Fundus imaging, OCT measurements of retinal thickness, and immunohistochemical data indicated an absence of retinal inflammation, and ERG indicated no impact on retinal function. The half-time of HyStem clearance calculated from the loss of fundus fluorescence was 3.9 days. Conclusions: HyStem hydrogel appears to be biocompatible in the ocular space of a large eye and safe for long-term intraocular application.
Authors: Glenn D Prestwich; Isaac E Erickson; Thomas I Zarembinski; Michael West; William P Tew Journal: Acta Biomater Date: 2012-07-07 Impact factor: 8.947
Authors: Douglas J Cook; Cynthia Nguyen; Hyun N Chun; Irene L Llorente; Abraham S Chiu; Michal Machnicki; Thomas I Zarembinski; S Thomas Carmichael Journal: J Cereb Blood Flow Metab Date: 2016-07-20 Impact factor: 6.200
Authors: Thomas I Zarembinski; Nathaniel J Doty; Isaac E Erickson; Ramya Srinivas; Barbara M Wirostko; William P Tew Journal: Acta Biomater Date: 2013-10-01 Impact factor: 8.947
Authors: Yong Liu; Ruilin Wang; Thomas I Zarembinski; Nate Doty; Caihui Jiang; Caio Regatieri; Xinmei Zhang; Michael J Young Journal: Tissue Eng Part A Date: 2012-10-12 Impact factor: 3.845
Authors: Jin Zhong; Albert Chan; Leeron Morad; Harley I Kornblum; Guoping Fan; S Thomas Carmichael Journal: Neurorehabil Neural Repair Date: 2010-04-27 Impact factor: 4.895
Authors: William F Hynes; Nate J Doty; Thomas I Zarembinski; Michael P Schwartz; Michael W Toepke; William L Murphy; Sarah K Atzet; Ryan Clark; J Andres Melendez; Nathaniel C Cady Journal: Biosensors (Basel) Date: 2014-03